Chabiotech Co.,Ltd. (KOSDAQ:085660)

Market Cap	927.42B
Revenue (ttm)	1.15T
Net Income (ttm)	-76.25B
Shares Out	75.96M
EPS (ttm)	-1,338.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	273,443
Average Volume	535,103
Open	12,270
Previous Close	12,340
Day's Range	12,040 - 12,330
52-Week Range	9,260 - 17,260
Beta	0.41
RSI	54.78
Earnings Date	Nov 13, 2025

About Chabiotech

Chabiotech Co.,Ltd., a bio company, develops cell and gene therapy related to stem and immune cells in South Korea and internationally. The company provides an umbilical cord blood consignment storage for the treatment of incurable diseases; regenerative medicines, immune cell and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs, comprising fitness, spa, and scupplements; and customized development, production, clinical, and commercialization services to customers with research and developm...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 278
• Stock Exchange: KOSDAQ
• Ticker Symbol: 085660

Financial Performance

In 2024, Chabiotech's revenue was 1.05 trillion, an increase of 9.55% compared to the previous year's 953.95 billion. Losses were -8.05 billion, -4.48% less than in 2023.